The editorial board and the Brazilian Urology Society are very proud with consolidation of the International Brazilian Journal of Urology as one of the most relevant in the dissemination of urology research worldwide.The September-October 2021 number of Int Braz J Urol, the 13th under my supervision, presents original contributions with a lot of interesting papers in different fields: Renal Cell Carcinoma, Bladder Cancer, SARS-CoV-2 and Urology, Basic Research applied to prostatic diseases, Premature ejaculation, Reconstructive urology, Lower urinary stones, Ureteral Stones, Lower urinary tract symptoms in children and Xanthogranulomatous Pyelonephritis. The papers came from many different countries such as Brazil, USA, Iran, Israel, Colombia and Singapure, and as usual the editor´s comment highlights some of them.Dr. Sharma and colleagues from India performed in page 921 (1) a nice sistematic review about the on-demand use of tramadol in premature ejaculation (PE) and concluded that Tramadol appears to be an effective drug for the management of PE with a low propensity for serious adverse events. However, evidence obtained from authors study is of low to moderate quality. Furthermore, effective dose and duration of therapy remain elusive.Dr. Dispagna and colleagues from USA (2) present in page 935 an important narrative review about the Management of Variant Histology in Renal Cell Carcinoma (RCC) and concluded that clinical management should be considered and adjusted for patients with non-clear-cell RCC histological variants based on tumor subtype and genetic alterations.